Vol. 6, Issue 2, Part A (2024)

Introduction: "coronavirus disease 2019" is a pandemic of acute respiratory sickness that was triggered by the highly transmissible and dangerous coronavirus, SARS-CoV-2, which poses risks to both public health and safety. The ADMET and bioactive properties of bioactive metabolites of A. indica leaf were predicted in the search for potential drug(s) for treatment and management of COVID-19. 
Research Method: The pharmacokinetic properties of 12 secondary metabolites from A. indica and 5 FDA approved drugs for treatment of COVID-19 were predicted using SWISSADME and ADMET lab online tools and Molinspiration server for bioactivity prediction. 
Results: The bioactive secondary metabolites and the drugs showed good ADMET and bioactivity properties, but ivermectin, azadirachtin A, azadirachtin D, azadirachtin H, azadirachtin F, azadirachtin I and nimbolin, have relatively poor properties. Similarly, most of the compounds have relatively tolerable toxicity level but remdesivir and nimboline. However, compounds from A. indica showed better properties in comparison to the FDA approved drug for COVID-19 treatment. 
Conclusion: Some of these compounds from A. indica leaf have relatively good ADMET and bioactive properties, and hence the need to dock them with human ACE2 in order to evaluate their binding interactions and thus their respective inhibitory constants.